Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia

American Journal of Hematology

Volumn 62, Issue 4, 1999, Pages 221-227

  Hoppe, Carolyn ^a   Vichinsky, Elliott ^a   Lewis, Bradley ^b   Foote, Dru ^a   Styles, Lori ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b Alta Bates Medical Center   (United States)

Author keywords

Hydroxyurea; Phenylbutyrate; Thalassemia; Therapy

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; HEMOGLOBIN F; HYDROXYUREA;

ADULT; ARTICLE; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; HEMOGLOBIN DETERMINATION; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; THALASSEMIA;

ADULT; BETA-THALASSEMIA; CAMBODIA; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; FETAL HEMOGLOBIN; HEMOGLOBINS; HUMANS; HYDROXYUREA; LAOS; MALE; PHENYLBUTYRATES; PHILIPPINES; VIETNAM;

EID: 0032709471     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199912)62:4<221::AID-AJH4>3.0.CO;2-R     Document Type: Article

References (26)

1. Weatherall DJ. The Thalassemias. In: Stamatoyannopoulos G, Nienhuis, AW, editors. The Molecular Basis of Blood Diseases. 2nd edition. Philadelphia: WB Saunders; 1994, p 157.
2. Winichagoon P, Thonglairoam V, Fucharoen S, Wilairat P, Fukumaki Y, Wasi P. Severity differences in β-thalassaemia/haemoglobin E syndromes: implication of genetic factors. Br J Haemotol 1993;83:633.
3. Saxon BR, Rees D, Olivieri NF. Regression of extramedullary haematopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in β-thalassaemia. Br J Haemotol 1998;101: 416.
4. Huang S-Z, Ren Z-R, Chen M-J, Xu H-P, Zeng Y-T, Rodgers GP. Treatment of β-thalassemia with hydroxyurea (HU)-Effects of HU on globin gene expression. Sci China 1994;37:1350.
5. Rigano P, Manfre L, La Galla R, Renda D, Renda MC, Calabrese A, Calzolari R, Maggio A. Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/β-thalassemia. Hemoglobin 1997;21:219.
6. Hajjar FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr 1994;125:490.
7. Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in β-thalassemia/hemoglobin E disease. Blood 1996;87:887.
8. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 1995;85:43.
9. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR, and the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317.
10. Rodgers GP. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: The National Institutes of Health experience. Semin Oncol 1992;19:67.
11. Pearson HA. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Adv Pediatr 1996;43:309.
12. Zeng Y-T, Huang S-Z, Ren Z-R, Lu Z-H, Zeng F-Y, Schecter AN, Rodgers GP. Hydroxyurea therapy in β-thalassemia intermedia: improvement in haematological parameters due enhanced β-globin synthesis. Br J Haemotol 1995;90:557.
13. Olivieri NF. Reactivation of fetal hemoglobin in patients with betathalassemia. Semin Hematol 1996;33:24.
14. Steinberg MH, Hebbel RP. Clinical diversity of sickle cell anemia: genetic and cellular modulation of disease severity. Am J Hematol 1983;14:405.
15. Aker M, Dover G, Schrier S, Rachmilewitz EA. Combination of erythropoietin and hydroxyurea results in improved quality and quantity of RBC in 7 patients with thalassemia intermedia. In: Beuzard Y, Lubin B, Rosa J, editors. Sickle Cell Disease and Thalassaemias: New Trends in Therapy. London: John Libbey Eurotext: 1995. p 197.
16. Cohen AR, Martin MB, Schwartz E. Hydroxyurea therapy in thalassemia intermedia. In: Beuzard Y, Lubin B, Rosa J, editors. Sickle Cell Disease and Thalassaemias: New Trends in Therapy. London: John Libbey Eurotext; 1995. p 193.
17. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994;84:339.
18. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP, Olivieri NF. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med 1993;328:81.
19. Sher GD, Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies. N Engl J Med 1995;332:1606.
20. Perrine SP, Miller BA, Papayannopoulou T, Faller DV, Rudolph AM, Vichinsky E, Hurst D, Kan YW. Butyrate analogues modulate globin gene expression in human and ovine erythroid cells. Prog Clin Biol Res 1989;341.
21. Singer K, Chernoff AI, Singer L. Studies on abnormal hemoglobins. I. Their demonstration in sickle cell anemia and other hematolgic disorders by means of alkali denaturation. Blood 1951;6:413.
22. McDonagh KT, Orringer EP, Dover G, et al. Hydroxyurea improves erythropoiesis in a patient with homozygous β-thalassemia. Clin Res 1990;38:346a.
23. Olivieri NF, Rees DC, Ginder GD, Thein SL, Brittenham GM, Waye JS, Weatherall DJ. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet 1997;350:491.
24. Wood A, Davies SC, Goldman J. A cross over study of hydroxyurea and sodium phenyl butyrate in sickle cell anaemia (HB SS). Blood 1995;86:140a.
25. Faller DV, Perrine SP. Butyrate in the treatment of sickle cell disease and β-thalassemia. Curr Opin Hematol 1995;2:109.
26. Liakopoulou E, Blau CA, Li Q, Josephson B, Wolf JA, Fournarakis B, Raisys V, Dover G, Papayannopoulou T, Stamatoyannopoulos G. Stimulation of fetal hemoglobin production by short chain fatty acids. Blood 1995;86:3227.